MiR-66-3b was identified as a potential diagnostic biomarker in a study by Yin et al., who isolated EVs (exosomes) from the plasma of BC patients and healthy controls, using the common exosomal markers CD9 and CD81. Here, CD9 is linked to breast cancer.